CAMBRIDGE, Mass., March 5, 2024 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage immunology company, today announced it will be providing updates on its RNA immunotherapies at multiple presentations at the American Association...
BioVaxys Technology Corp. has acquired the entire portfolio of discovery, preclinical and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX immune educating platform technology,...
Researchers at Cincinnati Children’s outlined two workflows for detecting new targets for cancer immunotherapies, one based on T cell antigens, the other upon B cell antigens. Credit: Cincinnati Children’s An innovative computational tool dubbed...
